Abstract Details

Title Self-Perceived Quality of Life and Related Clinical Conditions in Japanese Patients with Myasthenia Gravis: A Multicenter Cross-Sectional Study

Topic Muscle Disease/Neuromuscular Junction

Presentation(s) P02 - (-)

Poster/Presentation
Number 198

Objective

Background BACKGROUND: In our first survey of 327 Japanese MG patients in 2010, we verified the Japanese version of the 15-item MG-specific QOL scale (MG-QOL15-J) and assessed associations with clinical factors. The analysis identified three major factors negatively affecting QOL in MG patients for further examination in larger studies: disease severity, dose of oral corticosteroids and depressive conditions.

Design/Methods DESIGN/METHODS: In this survey, we evaluated 640 consecutive patients with MG seen at 11 neurological centers (Japan MG registry). All patients completed the MG-QOL15-J, and disease severity was assessed using the MG Foundation of America (MGFA) quantitative MG (QMG) and MG composite (MGC) scores. Clinical state following treatment was categorized according to MGFA postintervention status. Correlations between independent clinical factors and MG-QOL15-J score were determined by multivariate regression analysis.

Results RESULTS: Mean MG-QOL15-J, QMG and MGC scores in our cohort were 13.8±12.6, 7.0±5.2 and 5.2±6.1, respectively. Multivariate regression analysis of factors affecting QOL revealed that disease severity evaluated by MGC (p<0.0001) but not QMG (p=0.493), total dose of oral prednisolone during the last 1 year (p=0.002) but not current dose (p=0.211), Cushingoid appearance index (p=0.0004) and improved (I) MGFA postintervention status had a significant negative effect. Patient status of minimal manifestation (MM, p=0.0005), pharmacologic remission (PR, p=0.0001) and complete stable remission (CSR, p=0.005) had a significant positive effect on QOL. Mean MG-QOL15-J score was markedly lower (i.e., good QOL) for patients having status of MM (8.6±8.6), PR (4.0±5.7) and CSR (3.6±6.8) than for patients with I status (18.7±12.6).

Conclusions CONCLUSIONS: Disease severity, dose of oral corticosteroids (total dose during the last 1 year), Cushingoid appearance and not achieving MM status are major factors negatively affecting QOL.

Authors/Disclosures
Masayuki Masuda PRESENTER	Masayuki Masuda has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alexion pharma, Argenix pharma, Aasahi kasei pharma, UCB, Takeda pharma.
Kimiaki Utsugisawa, MD, PhD (Hanamaki General Hospital)	Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Utsugisawa has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB pharma. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen pharma. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chugai. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubisi Tanabe pharma. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Utsugisawa has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for argenx. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion phama. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Japan Blood Products Organization. Dr. Utsugisawa has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB.
	No disclosure on file
	No disclosure on file
Yuriko Nagane, MD, PhD (Hanamaki General Hospital, Neurology Dept)	No disclosure on file
Hiroyuki Murai, MD (International University of Health and Welfare)	Dr. Murai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Murai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Murai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Murai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chugai Pharmaceutical. Dr. Murai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Murai has received research support from Japan Blood Products Organization.
	No disclosure on file
	No disclosure on file
Shingo Konno, MD	Dr. Konno has nothing to disclose.
Shunya Nakane, MD	No disclosure on file
	No disclosure on file
Norihiro Suzuki	No disclosure on file

��ɫ��

��ɫ��